-
Views
-
Cite
Cite
Philippe A Cassier, Sawsan Abou-Amara-Olivieri, Pascal Artru, Marie-George Lapalus, Jean-Paul Riou, Catherine Lombard-Bohas, Mifepristone for ectopic ACTH secretion in metastatic endocrine carcinomas: report of two cases, European Journal of Endocrinology, Volume 158, Issue 6, Jun 2008, Pages 935–938, https://doi.org/10.1530/EJE-07-0792
- Share Icon Share
Abstract
Ectopic adrenocorticotropin secretion (EAS) remains a therapeutic challenge whenever the tumor responsible for the syndrome is not amenable to curative resection. Two cases of EAS related to metastatic foregut-derived endocrine carcinomas led us to use mifepristone, an antagonist of both progesterone and glucocorticoids. Mifepristone clearly improved skin lesions and diabetes associated with hypercorticism. The beneficial effect lasted for about 10 months. In both cases, recurrent hypertension and hypokalemia eventually required adrenalectomy.